Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324027 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31090251 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| Hexaethylene Glycol SCHEMBL6324969 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469395 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469742 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL197305 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469885 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9361385 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL12469729 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL4431897 | 0.97 | TSHR (0.53) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151608-A1 | CONNECTING UNITS FOR LIGAND-DRUG CONJUGATES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-11932603-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-109694362-B | 3-arylbenzofuranone propionamide compound, composition formed by same, preparation method and application thereof | 江苏裕事达新材料科技有限责任公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-109651275-B | Triazine compound, composition and preparation method thereof | 江苏裕事达新材料科技有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220227711-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-11332445-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220047718-A1 | Nanoparticle-Based Therapy of Inflammatory Disorders | MIDATECH LTD (GB) | 2022-02-17 | — | — | US | disclosed |
| EP-3893938-A1 | ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE | Midatech Ltd (GB) | 2021-10-20 | — | — | EP | disclosed |
| EP-3893939-A1 | NANOPARTICLE-BASED THERAPY OF INFLAMMATORY DISORDERS | Midatech Ltd (GB) | 2021-10-20 | — | — | EP | disclosed |
| CN-113423433-A | Nanoparticles carrying antifolates and their use in medicine | MIDA科技有限公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-2579898-A1 | PEPTIDE-CARRYING NANOPARTICLES | Midatech Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012170828-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | MONOSOL RX, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH PHARMA PLC (GB) | 2012-07-05 | — | — | US | disclosed |
| WO-2012049453-A2 | COMPOSITIONS FOR TOPICAL APPLICATIONS | VECTUM PHARMA S.L. (ES) | 2012-04-19 | — | — | WO | disclosed |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | AQUESTIVE THERAPEUTICS, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2010135800-A1 | INHIBITING OXIDATION AND IMMOBILIZING BIOMOLECULES ON A HYDROGEN-TERMINATED CRYSTALLINE SILICON SUBSTRATE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-12-02 | — | — | WO | disclosed |
| EP-1137628-A1 | MOLECULAR SCAFFOLDS ACTING AS TEMPLATES COMPRISING CARBAMATE LINKAGES | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034231-A1 | MOLECULAR SCAFFOLDS ACTING AS TEMPLATES COMPRISING CARBAMATE LINKAGES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-0292128-A1 | Improved DNA probes | TAMIR BIOTECHNOLOGY LTD (IL) | 1988-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | CALCA, LNPEP, CLTA | MEN1 1777/4885KMT2A 2914/4885TSHR 1406/4885 |
| US-11332445-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | ACR, HACD3, FCGR3B | MEN1 3362/4885KMT2A 4748/4885TSHR 350/4885 |
| US-20120009260-A1 | NANOPARTICLE FILM DELIVERY SYSTEMS | CD63, DSTN, EPCAM | MEN1 1868/4885KMT2A 3018/4885TSHR 2655/4885 |
| US-20220227711-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | ACR, HACD3, FCGR3B | MEN1 3362/4885KMT2A 4748/4885TSHR 350/4885 |
| US-20120301535-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | CALCA, LNPEP, IAPP | MEN1 1383/4885KMT2A 3874/4885TSHR 757/4885 |
| US-20220047718-A1 | Nanoparticle-Based Therapy of Inflammatory Disorders | MTX1, LANCL1, CD44 | MEN1 2325/4885KMT2A 2964/4885TSHR 3244/4885 |
| US-11932603-B2 | Hydrophilic high quantum yield acridinium esters with improved stability and fast light emission | ACR, HACD3, FCGR3B | MEN1 3362/4885KMT2A 4748/4885TSHR 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.